Singapore markets closed

Galapagos NV (GLPG)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
36.74+0.24 (+0.66%)
At close: 04:00PM EST
36.74 0.00 (0.00%)
Pre-market: 08:18AM EST
Full screen
Trade prices are not sourced from all markets
Previous close36.50
Bid0.00 x 900
Ask0.00 x 800
Day's range36.49 - 37.19
52-week range31.86 - 45.21
Avg. volume125,247
Market cap2.423B
Beta (5Y monthly)0.03
PE ratio (TTM)N/A
EPS (TTM)-2.53
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est44.43
  • Insider Monkey

    Galapagos NV (NASDAQ:GLPG) Q4 2023 Earnings Call Transcript

    Galapagos NV (NASDAQ:GLPG) Q4 2023 Earnings Call Transcript February 23, 2024 Galapagos NV beats earnings expectations. Reported EPS is $2.39, expectations were $-2.23. Galapagos NV isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank you for standing […]

  • GlobeNewswire

    Galapagos announces full year 2023 results and outlook for 2024

    Full year 2023 key financials: Group net revenues of €783.5 million, including Jyseleca® net sales of €112.3 million Cash and current financial investments of €3.7 billion on 31 December 2023Operational cash burni of €414.8 million, within guidance 2023 and year-to-date key updates: Transferred Jyseleca® business, including approximately 400 positions, to Alfasigma S.p.A.Achieved encouraging data from ongoing Phase 1/2 studies with CD19 CAR-T product candidates, GLPG5101 in rrNHL and GLPG5201, i

  • GlobeNewswire

    Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline

    - First participant dosed in Phase 1/2 PROSPER trial of FMC-376 in KRASG12C Cancers - FMC-376 is a first-in-class direct dual inhibitor of ON+OFF KRASG12C- FMC-376 has the potential to transform patient outcomes with its ability to overcome both innate and acquired resistance mechanisms and brain metastases BOSTON and SOUTH SAN FRANCISCO, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance transformation